Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "IDA"

2294 News Found

Vijaya Diagnostic Centre posts Q4 FY24 consolidated PAT at Rs. 33.45 Cr
News | May 09, 2024

Vijaya Diagnostic Centre posts Q4 FY24 consolidated PAT at Rs. 33.45 Cr

The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024


Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr
News | May 09, 2024

Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr

The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024


Suven Life Sciences posts Q4 FY24 consolidated loss at Rs. 26.54 Cr
News | May 07, 2024

Suven Life Sciences posts Q4 FY24 consolidated loss at Rs. 26.54 Cr

The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024


Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs
News | May 04, 2024

Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs

The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024


Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr
News | May 04, 2024

Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr

The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024


Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
News | May 04, 2024

Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr

The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024


Laurus Labs posts Q4 FY24 consolidated PAT at Rs. 75.61 Cr
News | April 26, 2024

Laurus Labs posts Q4 FY24 consolidated PAT at Rs. 75.61 Cr

Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024


Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
News | April 25, 2024

Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr

Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024


GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Drug Approval | April 17, 2024

GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA

Submission based on results from pivotal phase III trial showing all primary endpoints met


EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer
Drug Approval | March 07, 2024

EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer

The validations confirm the completion of the applications and commence the scientific review process